Acceleron Pharma Inc. (XLRN) Drops 9.9% on January 06

Equities Staff |

Acceleron Pharma Inc. (XLRN) was one of the Russell 2000's biggest losers for Wednesday January 06 as the stock slid 9.9% to $36.24, a loss of $-3.98 per share. Starting at an opening price of $40.00 a share, the stock traded between $35.45 and $40.09 over the course of the trading day. Volume was 2.72 million shares over 19,981 trades, against an average daily volume of 258,509 shares and a total float of 33.25 million.

The losses send Acceleron Pharma Inc. down to a market cap of $1.21 billion. In the last year, Acceleron Pharma Inc. has traded between $50.86 and $20.00, and its 50-day SMA is currently $40.01 and 200-day SMA is $33.07.

Acceleron Pharma Inc is a biopharmaceutical company. It focuses on the discovery, development & commercialization of novel therapeutic candidates based on the mechanisms that the human body uses to regulate the growth & repair of its cells and tissues.

Acceleron Pharma Inc. is based out of Cambridge, MA and has some 83 employees. Its CEO is John L. Knopf.

For a complete fundamental analysis analysis of Acceleron Pharma Inc., check out’s Stock Valuation Analysis report for XLRN. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Private Markets


Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…